Literature DB >> 2781859

Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine.

S I Tamura1, Y Samegai, H Kurata, K Kikuta, T Nagamine, C Aizawa, T Kurata.   

Abstract

Effects of the B subunit of cholera toxin (CTB) on the primary antibody responses to influenza virus A/PR/8/34 (PR-8) (H1N1) HA vaccine and on protection against viral challenge were investigated in Balb/c mice which were immunized intranasally with both the vaccine and CTB. The dose of CTB (greater than or equal to 1 microgram) inoculated with the vaccine (greater than or equal to 0.15 microgram) induced high responses of both antiviral IgA antibodies in the nasal wash and haemagglutinin-inhibiting (HI) antibody in the serum, enough to provide complete protection against viral challenge four weeks after immunization. High levels of antibody were maintained for more than 16 weeks after inoculation, affording complete protection during this interval. The inoculation of HA vaccine prepared from influenza viruses A/Yamagata/120/86 (H1N1) or A/Fukuoka/C29/85 (H3N2) together with CTB provided partial protection against PR-8 infection, with production of antiviral IgA antibodies which were cross-reactive to PR-8 antigens whereas immunization with CTB and HA vaccine prepared from a different type of influenza virus (B/Ibaraki/2/85) failed to protect against PR-8 infection. These results indicate that CTB can produce an augmented and persistent antibody response to PR-8 HA vaccine, which is cross-protective to other A-type virus infections. The mechanisms by which CTB enhances the protective antibody responses to the nasally inoculated vaccine were investigated. The ability of CTB to augment antibody responses was lost, either when CTB was inoculated via the intravenous or subcutaneous route, or when CTB was introduced into nasal site one day before or after the vaccine inoculation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2781859     DOI: 10.1016/0264-410x(89)90240-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Involvement of antigen-presenting cells in the enhancement of the in vitro antibody responses by cholera toxin B subunit.

Authors:  Y Hirabayashi; S I Tamura; K Shimada; T Kurata
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

2.  Rotavirus virus-like particles administered mucosally induce protective immunity.

Authors:  C M O'Neal; S E Crawford; M K Estes; M E Conner
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Distribution, persistence, and recall of serum and salivary antibody responses to peroral immunization with protein antigen I/II of Streptococcus mutans coupled to the cholera toxin B subunit.

Authors:  M W Russell; H Y Wu
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

Review 4.  Influenza vaccines. A reappraisal of their use.

Authors:  A M Palache
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 5.  Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system.

Authors:  H Y Wu; M W Russell
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

6.  Induction of antibody-secreting cells and T-helper and memory cells in murine nasal lymphoid tissue.

Authors:  H Y Wu; E B Nikolova; K W Beagley; M W Russell
Journal:  Immunology       Date:  1996-08       Impact factor: 7.397

7.  Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit.

Authors:  H Y Wu; M W Russell
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

8.  Protective salivary immunoglobulin A responses against Streptococcus mutans infection after intranasal immunization with S. mutans antigen I/II coupled to the B subunit of cholera toxin.

Authors:  J Katz; C C Harmon; G P Buckner; G J Richardson; M W Russell; S M Michalek
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

9.  Enhancement of anti-Shigella lipopolysaccharide (LPS) response by addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a LPS vaccines.

Authors:  N Orr; R Arnon; G Rubin; D Cohen; H Bercovier; G H Lowell
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

10.  An MDCK cell culture-derived formalin-inactivated influenza virus whole-virion vaccine from an influenza virus library confers cross-protective immunity by intranasal administration in mice.

Authors:  Ahmad M Haredy; Nobuyuki Takenaka; Hiroshi Yamada; Yoshihiro Sakoda; Masatoshi Okamatsu; Naoki Yamamoto; Takeshi Omasa; Hisao Ohtake; Yasuko Mori; Hiroshi Kida; Koichi Yamanishi; Shigefumi Okamoto
Journal:  Clin Vaccine Immunol       Date:  2013-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.